Search Results - TM

ALTIRATINIB (DCC-2701)

Background Information: Abstract (Ref 1): Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and...

M-3258 (M3258, M 3258)

M-3258 (CAS No.: 2285330-15-4), orally bioavailable, potent, reversible and highly selective immunoproteasome subunit LMP7 (β5i) inhibitor. M3258 exerts high biochemical (IC50=3.6 nM) and cellular (IC50=3.4 nM) potency against the LMP7 subunit. Synonyms: M3258, M 3258, M-3258,...